Tigecycline as a second-line agent for legionnaires' disease in severely ill patients

Deepika Slawek; Diana Altshuler; Yanina Dubrovskaya; Eddie Louie

doi:10.1093/ofid/ofx184

Tigecycline as a second-line agent for legionnaires' disease in severely ill patients

Deepika Slawek, Diana Altshuler, Yanina Dubrovskaya, Eddie Louie

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Treatment of Legionnaires' disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

Original language	English (US)
Article number	ofx184
Journal	Open Forum Infectious Diseases
Volume	4
Issue number	4
DOIs	https://doi.org/10.1093/ofid/ofx184
State	Published - Oct 1 2017
Externally published	Yes

Keywords

Legionnaires' disease
Tigecycline

ASJC Scopus subject areas

Oncology
Clinical Neurology

Access to Document

10.1093/ofid/ofx184

Cite this

@article{65cb989777aa4884b1710bf135852260,

title = "Tigecycline as a second-line agent for legionnaires' disease in severely ill patients",

abstract = "Treatment of Legionnaires' disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.",

keywords = "Legionnaires' disease, Tigecycline",

author = "Deepika Slawek and Diana Altshuler and Yanina Dubrovskaya and Eddie Louie",

note = "Publisher Copyright: {\textcopyright} The Author 2017.",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/ofid/ofx184",

language = "English (US)",

volume = "4",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Tigecycline as a second-line agent for legionnaires' disease in severely ill patients

AU - Slawek, Deepika

AU - Altshuler, Diana

AU - Dubrovskaya, Yanina

AU - Louie, Eddie

N1 - Publisher Copyright: © The Author 2017.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Treatment of Legionnaires' disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

AB - Treatment of Legionnaires' disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as second-line therapy. Clinical response was seen in most patients after switching to TG alone or as a combination therapy.

KW - Legionnaires' disease

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=85032858421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032858421&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofx184

DO - 10.1093/ofid/ofx184

M3 - Article

AN - SCOPUS:85032858421

SN - 2328-8957

VL - 4

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 4

M1 - ofx184

ER -

Tigecycline as a second-line agent for legionnaires' disease in severely ill patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this